This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound of the formula I



I

in which

R^1	is Het^1, or is a phenyl or naphthyl radical, each of which is unsubstituted or substituted by R^2 and/or R^3, ~~or is Het^1~~,
R^2 and R^3	are each, independently of one another, Hal, A, OA, OH or CN,
R^4	is H, CN, acyl having 1-6 C atoms, Hal, A, OA, OH, $CONH_2$, CONHA or $CONA_2$,
R^5	is H,
R^4 and R^5	together are alternatively alkylene having 3-5 carbon atoms,
Het^1	is a monocyclic unsaturated heterocyclic ring system which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH and which contains one, two or three identical or different heteroatoms selected from nitrogen, oxygen or sulfur,
A	is alkyl having 1-6 carbon atoms,
Hal	is F, Cl, Br or I,

wherein the R^1-CH_2-CH_2-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit, or

a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1*H*-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

2. (Previously Presented): A process for the preparation of a compound according to Claim 1, comprising:

a) reacting a compound of formula II



II

in which L is Cl, Br, I or a free or reactively functionally modified OH group,

with a compound of formula III



III

or

b) reacting a compound of formula IV



IV

with a compound of formula V

$$L\text{-}CH_2\text{-}CH_2\text{-}R^1 \qquad V$$

in which L is Cl, Br, I or a free or reactively functionally modified OH group,

or

c) one of the radicals R^1, R^4 and/or R^5 of a compound of claim 1 is converted into another radical R^1, R^4 and/or R^5 by cleaving an OA group to form an OH group and/or converting a CHO group into a CN group,

and/or

d) a base compound of claim 1 is converted into one of its salts by treatment with an acid,

and/or

e) a compound of claim 1 is converted into one of its solvates by dissolution in a solvent.

3. (Cancelled):

4. (Cancelled):

5. (Previously Presented): A method for treating psychosis, schizophrenia, depression, a neurological disorders, a memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, bulimia, nervous anorexia, premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD), comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

6. (Previously Presented): A pharmaceutical composition comprising at least one compound medicament according to Claim 1, and a carrier.

7. (Previously Presented): A method of preparing a medicament having a 5-HT_{2A} receptor antagonistic action comprising combining a compounds according to Claim 1 with a carrier.

8. (Cancelled):

9. (Previously Presented): A compound according to claim 1, wherein said compound is in the form of a hydrate or an alcoholate.

10. (Previously Presented): A compound according to claim 1, wherein R^4 is H, CN, formyl, acetyl, propionyl, butyryl, trifluoroacetyl, Hal, A, OA, OH, $CONH_2$, CONHA or $CONA_2$.

11. (Previously Presented): A compound according to claim 1, wherein R^1 is phenyl, p-chlorophenyl, p-fluorophenyl, thiophen-2-yl, 5-chlorothiophen-2-yl, 2,5-dichlorothiophen-3-yl and 2- or 3-furyl.

12. (Currently Amended): A compound according to claim 1, wherein R^4 is ~~and R^5 are, in each case independently,~~ H, Hal, alkyl having 1-6 C atoms, alkoxy having 1-6 C atoms, hydroxyl, cyano or acyl having 1-6 C atoms.

13. (Previously Presented): A compound according to claim 1, wherein R^4 is H, Hal, A, OA, OH, CN or acyl having 1-6 C atoms.

14. (Cancelled):

15. (Cancelled):

16. (Cancelled):

17. (Previously Presented): A compound according to claim 1, wherein R^1 is a phenyl radical which is unsubstituted or substituted by R^2 and/or R^3.

18. (Previously Presented): A compound according to claim 9, wherein R^1 is a phenyl radical which is unsubstituted or substituted by R^2 and/or R^3.

19. (Previously Presented): A compound according to claim 1, wherein R^1 is phenyl.

20. (Previously Presented): A compound according to claim 1, wherein R^1 is phenyl which is unsubstituted or monosubstituted by Hal.

21. (Currently Amended): A compound according to claim 1, wherein R^1 is Het^1 or phenyl which is monosubstituted by Hal ~~or Het^1~~.

22. (Currently Amended): A compound according to claim 1, wherein R^1 is Het^1 or phenyl which is unsubstituted or monosubstituted by Hal ~~or Het^1~~, and Het^1 is an unsaturated heterocyclic ring system which is unsubstituted or mono- or disubstituted by Hal or A and contains one or two identical or different heteroatoms selected from nitrogen, oxygen and sulphur.

23. (Currently Amended): A compound according to claim 1, wherein R^1 is Het^1 or phenyl which is unsubstituted or monosubstituted by Hal ~~or Het^1~~, R^4 is ~~and R^5 in each case independently of one another are~~ H, Hal or A, and Het^1 is an unsaturated heterocyclic ring system which is unsubstituted or mono- or disubstituted by Hal or A and contains one or two identical or different heteroatoms selected from nitrogen, oxygen and sulphur.

24. (Currently Amended): A compound according to claim 1, wherein R^1 is Het^1 or phenyl which is unsubstituted or monosubstituted by Hal ~~or Het^1~~, R^4 is ~~and R^5 in each case independently of one another are~~ H, Hal or A, or R^4 and R^5 together are alkylene having 3-5 C atoms, and Het^1 is thienyl or furyl which is unsubstituted or mono- or disubstituted by Hal or A.

25. (Currently Amended): A compound according to claim 1, wherein R^1 is Het^1 or phenyl which is unsubstituted or monosubstituted by Hal ~~or Het^1~~, R^4 is H, Hal, CN, acyl having 1 to 6 C atoms or A, ~~R^5 is H~~, or R^4 and R^5 together are alkylene having 3-5 C atoms, and Het^1 is thienyl or furyl which is unsubstituted or mono- or disubstituted by Hal or A.

26. (Currently Amended): A compound according to claim 1, wherein R^1 is Het^1 or phenyl which is unsubstituted or monosubstituted by Hal ~~or Het^1~~, R^4 is H, Hal, CN, acyl having 1 to 6 C atoms or A, ~~R^5 is H~~, or R^4 and R^5 together are alkylene having 3-5 C atoms, and Het^1 is thienyl or furyl which is unsubstituted or mono- or disubstituted by Hal or A, wherein the indole ring is optionally replaced by an isatin ring.

27. (Currently Amended): A compound according to claim 1, wherein said compound is:

(a) (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone or a physiologically acceptable salt or solvate thereof, or

(b) (3-aminocarbonyl-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone ~~3-aminocarbonyl-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone~~ or a physiologically acceptable salt or solvate thereof.

28. (Previously Presented): A compound according to claim 27, wherein said compound is in the form of a hydrate or an alcoholate.

29. (Previously Presented): A method for treating psychosis, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, bulimia, nervous anorexia, premenstrual syndrome and/or for positively influencing obsessive-compulsive disorder (OCD), comprising administering to a patient in need thereof an effective amount of a compound according to claim 27.

30. (Previously Presented): A pharmaceutical composition comprising at least one compound according to Claim 27 and a carrier.

31. (Previously Presented): A method for treating psychosis, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, bulimia, nervous anorexia, a sleep disorder, sleep apnoea, premenstrual syndrome, prophylaxis and combating of the consequences of cerebral infraction, strokes, and cerebral ischaemia, and/or for positively influencing obsessive-compulsive disorder, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

32. (Previously Presented): A method for treating psychosis, schizophrenia, depression, a neurological disorder, a memory disorder, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder, bulimia, nervous anorexia, a sleep disorder, sleep apnoea, premenstrual syndrome, prophylaxis and combating of the consequences of cerebral infraction, strokes, and cerebral ischaemia, and/or for positively influencing obsessive-compulsive disorder, comprising administering to a patient in need thereof an effective amount of a compound according to claim 27.

33. (Previously Presented): A method for treating a sleep disorder comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

34. (Previously Presented): A method for treating a sleep disorder comprising administering to a patient in need thereof an effective amount of a compound according to claim 27.

35. (Currently Amended) A compound of the formula I



I

in which

R^1	is Het^1 or is a phenyl or naphthyl radical, each of which is unsubstituted or substituted by R^2 and/or R^3, ~~or is Het^1~~;
R^2 and R^3	are each, independently of one another, Hal, A, OA, OH or CN,
R^4	is H, CN, acyl having 1-6 C atoms, Hal, A, OA, OH, $CONH_2$, CONHA or $CONA_2$,
R^5	is H,
R^4 and R^5	together are alternatively alkylene having 3-5 carbon atoms,
Het^1 ~~Het1~~	is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, ~~furthermore preferably~~ 1,2,3-triazol-1-, -4- or –5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or –5-yl, 1,2,4-oxadiazol-3- or –5-yl, 1,3,4-thiadiazol-2- or

-5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6 or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzthiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, ~~4-, 5-, 6- or 7-benzo-2,1,3-oxadiazolyl,~~ 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl,

A is alkyl having 1-6 carbon atoms,

Hal is F, Cl, Br or I,

wherein the R^1-CH_2-CH_2-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit, or

a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1*H*-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

36. (New): A compound of the formula I



I

in which

R^1 is Het^1 or a naphthyl radical which is unsubstituted or substituted by R^2 and/or R^3,

R^2 and R^3 are each, independently of one another, Hal, A, OA, OH or CN,

R^4 and R^5 are each, independently of one another, H, CN, acyl having 1-6 C atoms, Hal, A, OA or OH,

R^4 and R^5 together can also be alkylene having 3-5 C atoms,

Het^1 is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6 or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzthiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl,

A is alkyl having 1-6 carbon atoms,

Hal is F, Cl, Br or I,

and where the indole ring may be replaced by an isatin unit, or

a physiologically acceptable salt or solvate thereof.

37. (New): A compound of the formula I



I

in which

R^1	is Het^1 or a naphthyl radical which is unsubstituted or substituted by R^2 and/or R^3,
R^2 and R^3	are each, independently of one another, Hal, A, OA, OH or CN,
R^4 and R^5	are each, independently of one another, H, CN, acyl having 1-6 C atoms, Hal, A, OA or OH,
R^4 and R^5 together can also be alkylene having 3-5 C atoms,	
Het^1	is a monocyclic unsaturated heterocyclic ring system which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH and which contains one, two or three identical or different heteroatoms selected from nitrogen, oxygen or sulfur,
A	is alkyl having 1-6 carbon atoms,
Hal	is F, Cl, Br or I,

and where the indole ring may be replaced by an isatin unit, or

a physiologically acceptable salt or solvate thereof.

38. (New): A compound of the formula I



I

in which

R^1	is Het^1 or is a phenyl or naphthyl radical, which in each case is unsubstituted or substituted by R^2 and/or R^3,
R^2 and R^3	are each, independently of one another, Hal, A, OA, OH or CN,
R^4	is CN, acyl having 1-6 C atoms, Hal, A, OA or OH,
R^5	is H, CN, acyl having 1-6 C atoms, Hal, A, OA or OH,

R^4 and R^5 together can also be alkylene having 3-5 C atoms,

Het^1	is a monocyclic or bicyclic unsaturated heterocyclic ring system which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH and which contains one, two or three identical or different heteroatoms selected from nitrogen, oxygen or sulfur,
A	is alkyl having 1-6 carbon atoms,
Hal	is F, Cl, Br or I,

and where the indole ring may be replaced by an isatin unit, or

a physiologically acceptable salt or solvate thereof.

39. (New): A compound of the formula I



I

in which

R^1	is Het^1 or is a phenyl or naphthyl radical, which in each case is unsubstituted or substituted by R^2 and/or R^3,
R^2 and R^3	are each, independently of one another, Hal, A, OA, OH or CN,
R^4	is H, CN, acyl having 1-6 C atoms, Hal, A, OA or OH,

R^5	is CN, acyl having 1-6 C atoms, or Hal,
R^4 and R^5 together can also be alkylene having 3-5 C atoms,	
Het^1	is a monocyclic or bicyclic unsaturated heterocyclic ring system which is unsubstituted or monosubstituted or disubstituted by Hal, A, OA or OH and which contains one, two or three identical or different heteroatoms selected from nitrogen, oxygen or sulfur,
A	is alkyl having 1-6 carbon atoms,
Hal	is F, Cl, Br or I,

and where the indole ring may be replaced by an isatin unit, or a physiologically acceptable salt or solvate thereof.

40. (New): A compound according to claim 36, wherein the R^1-CH_2-CH_2-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring.

41. (New): A compound according to claim 37, wherein the R^1-CH_2-CH_2-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring.

42. (New): A compound according to claim 38, wherein the R^1-CH_2-CH_2-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring.

43. (New): A compound according to claim 39, wherein the R^1-CH_2-CH_2-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring.

44. (New): A compound according to claim 36, wherein the R^1 is Het^1.

45. (New): A compound according to claim 36, wherein R^1 is p-chlorophenyl, p-fluorophenyl, thiophen-2-yl, 5-chlorothiophen-2-yl, 2,5-dichlorothiophen-3-yl, 2- furyl or 3-furyl.

46. (New): A compound of the formula I



I

in which

R^1 is Het^1 or is a phenyl or naphthyl radical, each of which is unsubstituted or substituted by R^2 and/or R^3,

R^2 and R^3 are each, independently of one another, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, OH or CN,

R^4 is H, CN, formyl, acetyl, propionyl, butyryl, trifluoroacetyl, F, Cl, Br, I, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, OH, $CONH_2$, CONHA or

$CONA_2$,

A is methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1,2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2-, 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, or 1,1,2- or 1,2,2-trimethylpropyl,

R^5 is H,

R^4 and R^5 together are alternatively alkylene having 3-5 carbon atoms,

Het^1 is 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, 1,2,3-triazol-1-, -4- or –5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4- or –5-yl, 1,2,4-oxadiazol-3- or –5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thiadiazol-3- or –5-yl, 1,2,3-thiadiazol-4- or –5-yl, 2-, 3-, 4-, 5- or 6-2H-thiopyranyl, 2-, 3- or 4H-thiopyranyl, 3- or 4-pyridazinyl, pyrazinyl, 2-, 3-, 4-, 5-, 6- or 7-benzofuryl, 2-, 3-, 4-, 5-, 6- or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6 or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzthiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl,

A is alkyl having 1-6 carbon atoms,

Hal is F, Cl, Br or I,

wherein the R^1-CH_2-CH_2-piperazinecarbonyl radical is attached to the 4-, 5-, 6- or 7-position of the indole ring, and

where the indole ring may be replaced by an isatin unit, or

a physiologically acceptable salt or solvate thereof;

with the proviso that said compound is not (1*H*-indol-5-yl)-(4-phenethylpiperazin-1-yl)methanone.

47. (New): A compound selected from:

(1*H*-indol-4-yl)-(4-phenethylpiperazin-1-yl)methanone;

(1*H*-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;

(3-formyl-1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-phenethylpiperazin-1-yl)methanone;

(1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-6-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone,

(1*H*-indol-6-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;

(3-formyl-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(3-cyano-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone;

(1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-7-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-7-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-7-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
(3-formyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone,
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
(2,3-dimethyl-1*H*-indol-7-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-(4-phenethylpiperazin-1-yl)methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone; and
physiologically acceptable salts and solvates thereof.

48. (New): A compound according to claim 47, wherein said compound is (1*H*-indol-4-yl)-(4-phenethylpiperazin-1-yl)methanone, hydrochloride;
(1*H*-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(1*H*-indol-4-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone, hydrochloride;

(3-formyl-1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;

(1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;

(1*H*-indol-6-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;

(1*H*-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;

(1*H*-indol-6-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone, hydrochloride;

(3-cyano-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;

(1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone, hydrochloride;

(1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;

(1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;

(3-formyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;

(3-cyano-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride; or

(6,7,8,9-tetrahydro-5*H*-carbazol-3-yl)-(4-phenethylpiperazin-1-yl)methanone, hydrochloride.

49. (New): A compound according to claim 47, wherein said compound is selected from:

(1*H*-indol-4-yl)-(4-phenethylpiperazin-1-yl)methanone;

(1*H*-indol-4-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-4-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;

(1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(1*H*-indol-5-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
(1*H*-indol-5-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(1*H*-indol-5-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
(1*H*-indol-5-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
(3-formyl-1*H*-indol-5-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(1*H*-indol-6-yl)-[4-phenethylpiperazin-1-yl)methanone;
(1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(1*H*-indol-6-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
(1*H*-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(1*H*-indol-6-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone,
(1*H*-indol-6-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
(3-formyl-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1*H*-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-(4-phenethylpiperazin-1-yl)methanone;
(1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-[4-(thiophen-2-yl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-[4-(thiophen-3-yl)piperazin-1-yl]methanone;
(1*H*-indol-7-yl)-[4-(2,5-dichlorothiophen-3-yl)piperazin-1-yl]methanone;
(3-formyl-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1*H*-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone; and
physiologically acceptable salts and solvates thereof.

50. (New): A compound selected from:
(3-formyl-(1H-indol-6-y1)-[4-(4-fluorophenethyl)piperazin-1-y1]methanone;
(1H-indol-6-y1)-[4-(5-chlorothiophen-2-y1)piperazin-1-y1]methanone;
(1H-indol-4-y1)-[4-(5-chlorothiophen-2-y1)piperazin-1-y1]methanone;
(3-cyano-1H-indol-5-y1) -[4-(4-fluorophenethyl)piperazin-1-y1]methanone;

(3-cyano-1H-indol-7-yl)-[4-(naphtha-2-ylethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-4-yl)-[4- (4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-4-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-7-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone;
(3-aminocarbonyl-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-7-yl)-[4- (4- fluorophenethyl)piperazin-1-yl]methanone;
(3-cyano-1H-indol-7-yl)-[4- (5-chlorothiophen-2-yl)piperazin-1-yl]methanone; (3-cyano-1H-indol-7-yl-(4-phenethyl-piperazin-1-yl)methanone;
(3-cyano-1H-indol-7-yl) -[4-(2,4-difluorophenethyl)piperazin-1-yl]methanone;
7-{4-[2- (4-fluorophenyl) ethyl]piperazin-1-carbonyl} -1H- indole-2, 3-dione; and
physiologically acceptable salts and solvates thereof.

51. (New): A compound according to claim 50, wherein said compound is selected from:
(3-formyl-(1H-indol-6-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(1H-indol-6-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;
(1H-indol-4-yl)-[4-(5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-5-yl) -[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-7-yl)-[4-(naphtha-2-ylethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-4-yl)-[4- (4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-4-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-7-yl)-[4-(2-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-aminocarbonyl-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-7-yl)-[4- (4- fluorophenethyl)piperazin-1-yl]methanone, methanesulfonate;
(3-cyano-1H-indol-7-yl)-[4- (5-chlorothiophen-2-yl)piperazin-1-yl]methanone, hydrochloride;
(3-cyano-1H-indol-7-yl-(4-phenethyl-piperazin-1-yl)methanone, hydrochloride; and
(3-cyano-1H-indol-7-yl) -[4-(2,4-difluorophenethyl)piperazin-1-yl]methanone, hydrochloride.

52. (New): A compound according to claim 27, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.

53. (New): A compound according to claim 52, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.

54. (New): A compound according to claim 52, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.

55. (New): A method according to claim 29, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.

56. (New): A method according to claim 55, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.

57. (New): A method according to claim 55, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.

58. (New): A composition according to claim 30, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.

59. (New): A composition according to claim 58, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.

60. (New): A composition according to claim 58, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.

61. (New): A method according to claim 34, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.

62. (New): A method according to claim 61, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.

63. (New): A method according to claim 61, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.

64. (New): A method for treating scizophrenia comprising administering to a patient in need thereof an effective amount of a compound according to claim 27.

65. (New): A method according to claim 64, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, or a physiologically acceptable salt or solvate thereof.

66. (New): A method according to claim 65, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone.

67. (New): A method according to claim 65, wherein said compound is (3-cyano-1*H*-indol-7-yl)[4-(4-fluorophenethyl)piperazin-1-yl]-methanone, hydrochloride.

68. (New): A method according to claim 27, wherein said compound is administered to said patient at a daily dose of between 0.02 and 100 mg/kg of body weight.

69. (New): A method according to claim 29, wherein said compound is administered to said patient at a daily dose of between 0.02 and 100 mg/kg of body weight.

70. (New): A method according to claim 34, wherein said compound is administered to said patient at a daily dose of between 0.02 and 100 mg/kg of body weight.

71. (New): A method according to claim 64, wherein said compound is administered to said patient at a daily dose of between 0.02 and 100 mg/kg of body weight.